LSD-Perceptual-Choice-Study (LUCY)

This randomized, double-blinded, crossover trial (n=30) aims to characterise the effects of low doses of LSD on behavioural and neural indicators of feedback and feedforward signalling in perceptual decision-making.

Healthy participants will undergo multiple perceptual decision-making tasks after the administration of low doses of LSD or a placebo. The study seeks to understand the behavioural and neural effects of psychedelics on prior beliefs and evidence processing. Each subject will participate in three 5-hour study sessions separated by at least 7 days, under continuous supervision until approximately 4.5 hours after substance administration. Participants will perform cognitive tasks alongside EEG measurement after receiving either LSD or placebo, including the Changepoint task, history bias task, surround suppression task, auditory steady-state response paradigm, and motor localizer task.

The study commenced on February 20, 2024, with an estimated completion date of September 2024. It is being conducted by the University Hospital, Basel, Switzerland, with Professor Dr. Philipp Sterzer as the principal investigator.

Participants must be between 18 and 65 years old, have a body mass index between 18 and 29, fluent understanding of German, normal or corrected-to-normal vision, and willingness to adhere to study protocols. Exclusion criteria include recent participation in another clinical trial, pregnancy, current use of contraindicated drugs, severe medical conditions, hypertension or hypotension, current or lifetime major mental health disorders, and personal or family history of primary psychotic disorders.

Topic Healthy Subjects
Compound LSD Placebo
Country Switzerland
Visit trial
Status Recruiting
Results Published No
Start date 20 February 2024
End date 30 September 2024
Phase Not Applicable
Design Blinded
Type Interventional
Generation First
Participants 30
Sex All
Age 18- 65
Therapy No

Trial Details

The aim of the study is to characterize the effects of low doses of LSD (d-lysergic acid diethylamide) on behavioral and neural indicators of feedback and feedforward signaling in perceptual decision-making.

NCT Number NCT05976698

Sponsors & Collaborators

University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.